No­var­tis hands Re­genxbio $100M in fast cash for vec­tor tech

Re­genxbio is an ear­ly ben­e­fi­cia­ry of No­var­tis’ buy­out of AveX­is. The gene ther­a­py tech provider just picked up $100 mil­lion of ac­cel­er­at­ed pay­ments fol­low­ing the $8.7 bil­lion ac­qui­si­tion.

The com­pa­ny $RGNX says the pay­out in­cludes $60 mil­lion in an­nu­al fees and $40 mil­lion for a com­mer­cial mile­stone. An­oth­er $80 mil­lion mark­er is up for grabs along with roy­al­ties.

The pact with Re­genxbio now gives the phar­ma gi­ant an ex­clu­sive right to use the NAV Tech­nol­o­gy Plat­form for de­vel­op­ing new treat­ments for SMA, in­clud­ing AVXS-101, which us­es Re­genxbio’s NAV AAV9 vec­tor, the de­liv­ery ve­hi­cle.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER